NTRK1 and neuroblastoma: The therapeutic potential of targeting TrkAIII in NB has recently been demonstrated in a report of the durable and persistent (>5 years) response to compassionate entrectinib Alk/Trk inhibitor therapy in an infant with refractory, relapsed, metastatic, TrkAIII-expressing NB, in the context of exhausted treatment options [31].